Advertisement

Nachsorge des Mammacarcinoms

  • Marianne Schmid
  • Hellmut Samonigg
Chapter
  • 16 Downloads
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Nach der Primärbehandlung einer Mammacarcinomerkrankung muß mindestens zehn Jahre lang, gelegentlich auch länger als zwanzig Jahre lang, mit einer erneuten Tumormanifestation gerechnet werden. Bei jenen Patientinnen, die zehn Jahre die Nachsorge wahrnehmen, wird innerhalb dieses Zeitraumes eine jährliche Metastasierungsrate von 5% bis 10% beobachtet.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    ACOG Committee Opinion (1996) Tamoxifen and endometrium cancer: Committee opinion on gynecologic practice. J Am Coll of Obstetricians and Gynecologists: No. 169.Google Scholar
  2. [2]
    Baker RR, et al. (1977) An evaluation of bone scans as screening procedures for occult metastases in primary breast cancer. Ann Surg 186(3): 363–368.PubMedCrossRefGoogle Scholar
  3. [3]
    Bissett D, Davis JA, George WD (1994) Gynaecological monitoring during tamoxifen therapy. Lancet 344: 1244.PubMedCrossRefGoogle Scholar
  4. [4]
    Broyn T, Froyen J (1982) Evaluation of routine follow-up after surgery for breast carcinoma. Acta Chir Scand 148(5): 401–404.PubMedGoogle Scholar
  5. [5]
    Burkett FE, Scanion EF, Garces R, et al. (1979) The value of bone scans in the management of patients with carcinoma of the breast. Surg Gyncol Obstet 149(4): 523–525.Google Scholar
  6. [6]
    Ciatto S, et al. (1993) Cancer reoccurrence in the conserved breast: Diagnostic features in a consecutive series of 102 cases. Intl J Oncol 3: 337–339.Google Scholar
  7. [7]
    Corcoron RJ, et al. (1976) Solitary abnormalities in bone scans of patients with extraosseous malignancies. Radiology 121: 663–667.Google Scholar
  8. [8]
    Crivellari D, et al. (1995) Routine tests during follow-up of patients after primary treatment for operable breast cancer. Ann Oncol 6(g): 769–776.PubMedGoogle Scholar
  9. [9]
    Del Turco MR, et al. (1994) Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial: National Research Council Project on Breast Cancer Follow-Up. JAMA 271(20): 1593–1597.CrossRefGoogle Scholar
  10. [10]
    Dershaw DD, et al. (1992) Detection of local recurrence after conservative therapy for breast carcinoma. Cancer 70(2): 493–496.PubMedCrossRefGoogle Scholar
  11. [11]
    Dewar JA, Kerr GR (1985) Value of routine follow up of women treated for early carcinoma of the breast. BMJ 291: 1464–1467.PubMedCrossRefGoogle Scholar
  12. [12]
    Fisher B, et al. (1994) Endometrail cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP)B-14. J Natl Cancer Inst 86(7): 527–537.PubMedCrossRefGoogle Scholar
  13. [13]
    Hassell PR, et al. (1990) Early breast cancer: Detection of recurrence after conservative surgery and radiation therapy. Radiology 176(3): 731–735.PubMedGoogle Scholar
  14. [14]
    Hellriegel KP, Schulz HD (1995) Nachsorge bei Mammacarcinom-Patientinnen. Empfehlungen einer Consensus-Tagung, Berlin 23.-24. 02.1995. Onkologie 1: 405–412.Google Scholar
  15. [15]
    Hölzel D, et al. (1997) Nachsorge in Empfehlungen zur Diagnostik, Therapie und Nachsorge — Mammacarcinome, 6. Aufl., Nachdruck 1997. Schriftenreihe Tumorzentrum, München.Google Scholar
  16. [16]
    Jäger W, et al. (1995) Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest 55(Suppl. 221): 87–92.CrossRefGoogle Scholar
  17. [17]
    Kovner F, et al. (1994) Treatment of disease negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: Preliminary results of a prospective randomized study. Cancer Chemoth Pharmacol 35: 80–83.CrossRefGoogle Scholar
  18. [18]
    McNeil BJ, et al. (1978) Pre-operative and follow-up bone scans in patients with primary carcinoma of the breast. Surg Gyncol Obstet 147(5): 745–748.Google Scholar
  19. [19]
    Mellink WA, et al. (1991) The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 67(7): 1844–1848.PubMedCrossRefGoogle Scholar
  20. [20]
    Muss HB, et al. (1988) Follow-up after stage II breast cancer: A comparative study of relapsed versus nonrelapsed patients. Am J Clin Oncol (CCT) 11(4): 451–455.CrossRefGoogle Scholar
  21. [21]
    O’Connell MJ, et al. (1978) Value of preoperative radionucleotide bone scans in suspected primary breast cancer. Mayo Clin Pro 53(4): 221–226.Google Scholar
  22. [22]
    Orel SG, et al. (1993) Breast cancer recurrence after lumpectomy and radiation therapy for early-stage disease: Prognostic significance of detection method. Radiology 188(1): 189–194.PubMedGoogle Scholar
  23. [23]
    Orel SG, et al. (1992) Breast cancer recurrence after lumpectomy and irradiation: Role of mammography in detraction. Radiology 183(1): 201–206.PubMedGoogle Scholar
  24. [24]
    Orniston MC, et al. (1985) Is follow-up of patients after surgery for breast cancer worthwhile? J R Soc Med 78: 920–921.Google Scholar
  25. [25]
    Pandya KJ, et al. (1985) A retrospective study of earliest indicators of recurrence in patients on Eastern Cooperative Oncology Group Adjuvant Chemotherapy Trials for breast cancer. A preliminary report. Cancer 55(1): 202–205.PubMedCrossRefGoogle Scholar
  26. [26]
    Pedrazzini A, et al. (1986) First repeated bone scan in the observation of patients with operable breast cancer. J Clin Oncol 4(3): 389–394.PubMedGoogle Scholar
  27. [27]
    Perez DJ, et al. (1983) Detection of breast carcinoma metastases in bone: Relative merits of x-rays and skeletal scinitigraphy. Lancet 2: 613–616.PubMedCrossRefGoogle Scholar
  28. [28]
    Recommended Breast Cancer Surveillance Guidelines. Adopted on February 20, 1997 by the American Society for Clinical Oncology (ASCO). J Clin Oncol 15: 2147–2156.Google Scholar
  29. [29]
    Rossing N, et al. (1982) What do early bone scans tell about breast cancer patients? Eur J Cancer Clin Oncol 18: 629–636.PubMedCrossRefGoogle Scholar
  30. [30]
    Sauer H (1996) Empfehlungen zur Diagnostik, Therapie und Nachsorge-Mammacarcinome. Schriftenreihe Tumorzentrum München, 6. Auflage, Nachdruck 1997.Google Scholar
  31. [31]
    Scanion EF, et al. (1980) Preoperative and follow-up procedures on patients with breast cancer. Cancer 46(Suppl. 4): 77–79.Google Scholar
  32. [32]
    Schapira DV, Urban N (1991) A minimalist policy for breast cancer surveillance. JAMA 265(3): 380–382.PubMedCrossRefGoogle Scholar
  33. [33]
    Senofsky GM, et al. (1986) Has monitoring of the contralateral breast improved the prognosis in patients treated for primary breast cancer? Cancer 57(3): 579–602.CrossRefGoogle Scholar
  34. [34]
    Sismondi P, et al. (1994) Tamoxifen and endometrial cancer. Am NY Acad Sci 734: 310–321.CrossRefGoogle Scholar
  35. [35]
    The GIVIO Investigators (1994) Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. JAMA 271(20): 1587–1592.CrossRefGoogle Scholar
  36. [36]
    Van Leeuwen FE, et al. (1994) Risk of endmetrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448–452.PubMedCrossRefGoogle Scholar
  37. [37]
    Winchester DP, et al. (1979) Symptomatology as an indicator of recurrent or metastatic breast cancer. Cancer 43(3): 956–960.PubMedCrossRefGoogle Scholar
  38. [38]
    Zuziely B, et al. (1993) The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 26(1): 101–105.CrossRefGoogle Scholar
  39. [39]
    Zwaveling A, et al. (1987) An evaluation of routine follow-up for detection of breast cancer recurrences. J Surg Oncol 34(3): 194–197.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Marianne Schmid
    • 1
  • Hellmut Samonigg
    • 1
  1. 1.Klinische Abteilung für OnkologieMedizinische UniversitätsklinikGrazÖsterreich

Personalised recommendations